Guo, M; Wang, K; Qiao, N; Yardley, V; Li, M; (2018) Investigating Permeation Behavior of Flufenamic Acid Cocrystals Using a Dissolution and Permeation System. Molecular pharmaceutics. ISSN 1543-8384 DOI: https://doi.org/10.1021/acs.molpharmaceut.8b00670

Thompson, AM; O'Connor, PD; Marshall, AJ; Blaser, A; Yardley, V; Maes, L; Gupta, S; Launay, D; Braillard, S; Chatelain, E; +5 more... Wan, B; Franzblau, SG; Ma, Z; Cooper, CB; Denny, WA; (2018) Development of (6 R)-2-Nitro-6-[4-(trifluoromethoxy)phenoxy]-6,7-dihydro-5 H-imidazo[2,1- b][1,3]oxazine (DNDI-8219): A New Lead for Visceral Leishmaniasis. Journal of medicinal chemistry. ISSN 0022-2623 DOI: https://doi.org/10.1021/acs.jmedchem.7b01581

Van Bocxlaer, K; Gaukel, E; Hauser, D; Park, SH; Schock, S; Yardley, V; Randolph, R; Plattner, JJ; Merchant, T; Croft, SL; +2 more... Jacobs, RT; Wring, SA; (2018) Topical treatment for cutaneous leishmaniasis - dermato-pharmacokinetic led optimisation of benzoxaboroles. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.02419-17

Wijnant, GJ; Van Bocxlaer, K; Fortes Francisco, A; Yardley, V; Harris, A; Alavijeh, M; Murdan, S; Croft, SL; (2018) Local skin inflammation in cutaneous leishmaniasis as a source of variable pharmacokinetics and therapeutic efficacy of liposomal amphotericin B. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.00631-18

Wijnant, GJ; Van Bocxlaer, K; Yardley, V; Harris, A; Alavijeh, M; Silva-Pedrosa, R; Antunes, S; Mauricio, I; Murdan, S; Croft, SL; (2018) Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome® and AmBisome® in murine cutaneous leishmaniasis. International journal for parasitology Drugs and drug resistance, 8 (2). pp. 223-228. ISSN 2211-3207 DOI: https://doi.org/10.1016/j.ijpddr.2018.04.001

Yardley, V; Koniordou, M; (2018) Chapter 4: Drug Assay Methodology in Leishmaniasis: From the Microplate to Image Analysis. In: UNSPECIFIED, (ed.) Drug Discovery for Leishmaniasis. Royal Society of Chemistry, pp. 55-76. ISBN 9781782628897 DOI: https://doi.org/10.1039/9781788010177 Full text not available from this repository.

Basilico, N; Parapini, S; Sparatore, A; Romeo, S; Misiano, P; Vivas, L; Yardley, V; Croft, SL; Habluetzel, A; Lucantoni, L; +8 more... Renia, L; Russell, B; Suwanarusk, R; Nosten, F; Dondio, G; Bigogno, C; Jabes, D; Taramelli, D; (2017) In Vivo and In Vitro Activities and ADME-Tox Profile of a Quinolizidine-Modified 4-Aminoquinoline: A Potent Anti-P. falciparum and Anti-P. vivax Blood-Stage Antimalarial. Molecules (Basel, Switzerland), 22 (12). ISSN 1420-3049 DOI: https://doi.org/10.3390/molecules22122102

Bhambra, AS; Ruparelia, KC; Tan, HL; Tasdemir, D; Burrell-Saward, H; Yardley, V; Beresford, KJ; Arroo, RR; (2017) Synthesis and antitrypanosomal activities of novel pyridylchalcones. European journal of medicinal chemistry, 128. pp. 213-218. ISSN 0223-5234 DOI: https://doi.org/10.1016/j.ejmech.2017.01.027

Thompson, AM; O'Connor, PD; Marshall, AJ; Yardley, V; Maes, L; Gupta, S; Launay, D; Braillard, S; Chatelain, E; Franzblau, SG; +5 more... Wan, B; Wang, Y; Ma, Z; Cooper, CB; Denny, WA; (2017) 7-Substituted 2-Nitro-5,6-dihydroimidazo[2,1-b][1,3]oxazines: Novel Antitubercular Agents Lead to a New Preclinical Candidate for Visceral Leishmaniasis. Journal of medicinal chemistry, 60 (10). pp. 4212-4233. ISSN 0022-2623 DOI: https://doi.org/10.1021/acs.jmedchem.7b00034

Wijnant, GJ; Van Bocxlaer, K; Yardley, V; Harris, A; Murdan, S; Croft, SL; (2017) AmBisome® treatment of murine cutaneous leishmaniasis: relation between skin pharmacokinetics and efficacy. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.02009-17

Wijnant, GJ; Van Bocxlaer, K; Yardley, V; Murdan, S; Croft, S; (2017) Efficacy of a Paromomycin plus Chloroquine Combination Therapy in Experimental Cutaneous Leishmaniasis. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.00358-17

Daunes, S; Yardley, V; Croft, SL; D'Silva, C; (2016) Antiprotozoal glutathione derivatives with flagellar membrane binding activity against T. brucei rhodesiense. Bioorganic & medicinal chemistry. ISSN 0968-0896 DOI: https://doi.org/10.1016/j.bmc.2016.12.016

Khan, NH; Bari, AU; Hashim, R; Khan, I; Muneer, A; Shah, A; Wahid, S; Yardley, V; O'Neil, B; Sutherland, CJ; (2016) Cutaneous Leishmaniasis in Khyber Pakhtunkhwa Province of Pakistan: Clinical Diversity and Species-Level Diagnosis. The American journal of tropical medicine and hygiene. ISSN 0002-9637 DOI: https://doi.org/10.4269/ajtmh.16-0343

Tegazzini, D; Díaz, R; Aguilar, F; Peña, I; Presa, JL; Yardley, V; Martin, JJ; Coteron, JM; Croft, SL; Cantizani, J; (2016) A replicative in vitro assay for drug discovery against Leishmania donovani. Antimicrobial agents and chemotherapy, 60 (6). pp. 3524-32. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.01781-15

Thompson, AM; O'Connor, PD; Blaser, A; Yardley, V; Maes, L; Gupta, S; Launay, D; Martin, D; Franzblau, SG; Wan, B; +3 more... Wang, Y; Ma, Z; Denny, WA; (2016) Repositioning Antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for Neglected Tropical Diseases: Structure-Activity Studies on a Preclinical Candidate for Visceral Leishmaniasis. Journal of medicinal chemistry. ISSN 0022-2623 DOI: https://doi.org/10.1021/acs.jmedchem.5b01699

Van Bocxlaer, K; Yardley, V; Murdan, S; Croft, SL; (2016) Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model. The Journal of pharmacy and pharmacology, 68 (7). pp. 862-72. ISSN 0022-3573 DOI: https://doi.org/10.1111/jphp.12548

Van Bocxlaer, K; Yardley, V; Murdan, S; Croft, SL; (2016) Drug permeation and barrier damage in Leishmania-infected mouse skin. The Journal of antimicrobial chemotherapy, 71 (6). pp. 1578-85. ISSN 0305-7453 DOI: https://doi.org/10.1093/jac/dkw012 Full text not available from this repository.

Yizengaw, E; Getahun, M; Tajebe, F; Cruz Cervera, E; Adem, E; Mesfin, G; Hailu, A; Van der Auwera, G; Yardley, V; Lemma, M; +10 more... Skhedy, Z; Diro, E; Yeshanew, A; Melkamu, R; Mengesha, B; Modolell, M; Munder, M; Müller, I; Takele, Y; Kropf, P; (2016) Visceral Leishmaniasis Patients Display Altered Composition and Maturity of Neutrophils as well as Impaired Neutrophil Effector Functions. Frontiers in immunology, 7. p. 517. ISSN 1664-3224 DOI: https://doi.org/10.3389/fimmu.2016.00517

Bhambra, AS; Edgar, M; Elsegood, MR; Li, Y; Weaver, GW; Arroo, RR; Yardley, V; Burrell-Saward, H; Krystof, V; (2015) Design, synthesis and antitrypanosomal activities of 2,6-disubstituted-4,5,7-trifluorobenzothiophenes. European journal of medicinal chemistry, 108. pp. 347-353. ISSN 0223-5234 DOI: https://doi.org/10.1016/j.ejmech.2015.11.043 Full text not available from this repository.

Carvalho, L; Martínez-García, M; Pérez-Victoria, I; Manzano, JI; Yardley, V; Gamarro, F; Pérez-Victoria, JM; (2015) The oral antimalarial drug tafenoquine shows activity against Trypanosoma brucei. Antimicrobial agents and chemotherapy. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.00879-15 Full text not available from this repository.

Corware, K; Yardley, V; Mack, C; Schuster, S; Al-Hassi, H; Herath, S; Bergin, P; Modolell, M; Munder, M; Müller, I; +1 more... Kropf, P; (2014) Protein energy malnutrition increases arginase activity in monocytes and macrophages. Nutrition & metabolism, 11 (1). p. 51. ISSN 1743-7075 DOI: https://doi.org/10.1186/1743-7075-11-51

Gupta, S; Yardley, V; Vishwakarma, P; Shivahare, R; Sharma, B; Launay, D; Martin, D; Puri, SK; (2014) Nitroimidazo-oxazole compound DNDI-VL-2098: an orally effective preclinical drug candidate for the treatment of visceral leishmaniasis. The Journal of antimicrobial chemotherapy. ISSN 0305-7453 DOI: https://doi.org/10.1093/jac/dku422 Full text not available from this repository.

Les, KA; Mohamed-Ahmed, AHA; Balan, S; Choi, J.-, W; Martin, D; Yardley, V; Powell, K; Godwin, A; Brocchini, S; (2014) Poly(methacrylic acid) complexation of amphotericin B to treat neglected diseases. Polymer chemistry, 5 (3). pp. 1037-1048. ISSN 1759-9954 DOI: https://doi.org/10.1039/c3py01051a Full text not available from this repository.

Sanderson, L; Yardley, V; Croft, SL; (2014) Activity of anti-cancer protein kinase inhibitors against Leishmania spp. The Journal of antimicrobial chemotherapy. ISSN 0305-7453 DOI: https://doi.org/10.1093/jac/dku069 Full text not available from this repository.

Decuypere, S; Vanaerschot, M; Rijal, S; Yardley, V; Maes, L; de Doncker, S; Chappuis, F; Dujardin, JC; (2008) Gene expression profiling of Leishmania (Leishmania) donovani: overcoming technical variation and exploiting biological variation. Parasitology, 135 (2). pp. 183-194. ISSN 0031-1820 DOI: https://doi.org/10.1017/S0031182007003782

Fattorusso, C; Campiani, G; Kukreja, G; Persico, M; Butini, S; Romano, MP; Altarelli, M; Rost, S; Brindisi, M; Savini, L; +10 more... Novellino, E; Nacci, V; Fattorusso, E; Parapini, S; Basilico, N; Taramelli, D; Yardley, V; Croft, S; Borriello, M; Gemma, S; (2008) Design, synthesis, and structure-activity relationship studies of 4-quinolinyl- and 9-acrydinylhydrazones as potent antimalarial agents. Journal of medicinal chemistry, 51 (5). pp. 1333-1343. ISSN 0022-2623 DOI: https://doi.org/10.1021/jm7012375 Full text not available from this repository.

Gemma, S; Kukreja, G; Fattorusso, C; Persico, M; Romano, MP; Altarelli, M; Savini, L; Campiani, G; Fattorusso, E; Basilico, N; +3 more... Taramelli, D; Yardley, V; Butini, S; (2006) Synthesis of N1-arylidene-N2-quinolyl- and N2-acrydinylhydrazones as potent antimalarial agents active against CQ-resistant P. falciparum strains. Bioorganic & medicinal chemistry letters, 16 (20). pp. 5384-8. ISSN 0960-894X DOI: https://doi.org/10.1016/j.bmcl.2006.07.060 Full text not available from this repository.

Laurent, T; Rijal, S; Yardley, V; Croft, S; De Doncker, S; Decuypere, S; Khanal, B; Singh, R; Schönian, G; Kuhls, K; +2 more... Chappuis, F; Dujardin, JC; (2006) Epidemiological dynamics of antimonial resistance in Leishmania donovani: Genotyping reveals a polyclonal population structure among naturally-resistant clinical isolates from Nepal. Infection, genetics and evolution, 7 (2). pp. 206-12. ISSN 1567-1348 DOI: https://doi.org/10.1016/j.meegid.2006.08.005 Full text not available from this repository.

Tasdemir, D; Brun, R; Yardley, V; Franzblau, SG; Rüedi, P; (2006) Antituberculotic and antiprotozoal activities of primin, a natural benzoquinone: in vitro and in vivo studies. Chemistry & biodiversity, 3 (11). pp. 1230-7. ISSN 1612-1872 DOI: https://doi.org/10.1002/cbdv.200690124 Full text not available from this repository.

Yardley, V; Croft, SL; DE Doncker, S; Dujardin, JC; Koirala, S; Rijal, S; Miranda, C; Llanos-Cuentas, A; Chappuis, F; (2005) THE SENSITIVITY OF CLINICAL ISOLATES OF LEISHMANIA FROM PERU AND NEPAL TO MILTEFOSINE. The American journal of tropical medicine and hygiene, 73 (2). pp. 272-5. ISSN 0002-9637 http://researchonline.lshtm.ac.uk/id/eprint/13280

Larabi, M; Yardley, V; Loiseau, PM; Appel, M; Legrand, P; Gulik, A; Bories, C; Croft, SL; Barratt, G; (2003) Toxicity and Antileishmanial Activity of a New Stable Lipid Suspension of Amphotericin B. Antimicrobial agents and chemotherapy, 47 (12). pp. 3774-3779. ISSN 0066-4804 DOI: https://doi.org/10.1128/AAC.47.12.3774-3779.2003 Full text not available from this repository.

Magaraci, F; Jimenez, CJ; Rodrigues, C; Rodrigues, JCF; Braga, MV; Yardley, V; de Luca-Fradley, K; Croft, SL; de Souza, W; Ruiz-Perez, LM; +3 more... Urbina, J; Pacanowska, DG; Gilbert, IH; (2003) Azasterols as inhibitors of sterol 24-methyltransferase in leishmania species and Trypanosoma cruzi. Journal of medicinal chemistry, 46 (22). pp. 4714-4727. ISSN 0022-2623 DOI: https://doi.org/10.1021/jm021114j Full text not available from this repository.